Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of ...
Vertex has begun a full-court press for Journavx, enlisting NBA All-Star Jayson Tatum to discuss his use of the new ...
The FDA granted breakthrough therapy designation to a Vertex Pharmaceuticals kidney disease drug.
Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback